Table 2 Processes of care at the onset of and treatment for the initial CDI hospitalization
Patient characteristics | Patients who developed rCDI | Patients who did not develop rCDI | Hazard ratio |
|---|---|---|---|
(n = 425) | (n = 3775) | 95% CI | |
Laboratory results iCDI onset | |||
Low albumin | 50 (12) | 548 (15) | 0.84 (0.63 – 1.13) |
Low WBC | 64 (15) | 635 (17) | 0.99 (0.82 – 1.20) |
High WBC | 247 (58) | 2027 (54) | 1.23 (1.01 – 1.49) |
Low hemoglobin | 218 (51) | 1985 (53) | 0.96 (0.79 – 1.16) |
High creatinine | 99 (23) | 862 (23) | 1.08 (0.86 – 1.35) |
Relevant medications present at iCDI onset | |||
Any antimicrobial | 314 (74) | 2729 (72) | 1.10 (0.88 – 1.36) |
Low risk antimicrobial(s)a | 95 (22) | 1058 (28) | 0.76 (0.60 – 0.95) |
High risk antimicrobial(s)b | 174 (41) | 1490 (40) | 1.07 (0.88 – 1.29) |
Fluoroquinolone | 120 (28) | 861 (23) | 1.29 (1.05 – 1.60) |
IV vancomycin | 130 (31) | 1321 (35) | 0.86 (0.70 – 1.05) |
Gastric acid suppressor, any | 310 (73) | 2850 (76) | 0.91 (0.73 – 1.12) |
New gastric acid suppressor | 54 (13) | 255 (7) | 1.87 (1.41 – 2.49) |
Relevant medications received following iCDI onset | |||
Any antibiotic first dose after CDI | 278 (65) | 1622 (43) | 2.47 (2.02 – 3.02) |
Low risk antimicrobial(s) first dose after CDIa | 141 (33) | 710 (19) | 2.09 (1.71 – 2.56) |
High risk antimicrobial(s) first dose after CDIb | 150 (35) | 714 (19) | 2.30 (1.89 – 2.81) |
Fluoroquinolone first dose after CDI | 124 (29) | 703 (19) | 1.69 (1.37 – 2.09) |
IV vancomycin first dose after CDI | 115 (27) | 337 (12) | 2.61 (2.11 – 3.23) |
Initial CDI treatment | |||
Metronidazole alone | 323 (76) | 2841 (75) | Reference |
Oral vancomycin alone | 16 (4) | 104 (3) | 1.32(0.80 – 2.18) |
Metronidazole and oral vancomycin | 86 (20) | 829 (22) | 0.95 (0.75 – 1.20) |